- 期刊
- OpenAccess
Preventive Agents for Migraine: Focus on the Antiepileptic Drugs
並列摘要
Migraine is among the 10 most disabling disorders worldwide. It is characterized by episodes of moderate or severe headaches with various degree of disability, resulting in a considerable health burden upon the sufferers and their family. The objective of this article is to review the use of prophylaxis with antiepileptic drugs. Particular focus is given to their mechanism of action, metabolism, pharmacokinetics, safety profile, efficacy and to provide a summary of the most relevant clinical studies and patient preference.
延伸閱讀
- MacGregor, E. A. (2011). Telcagepant: A New Therapeutic Option for Acute Migraine?. Clinical Medicine Insights: Therapeutics, 2011(), 301-314. https://doi.org/10.4137/CMT.S7477
- 吳如琇（2002）。Introduction to Antiepileptic Drugs。台灣醫學，6(2)，243-250。https://doi.org/10.6320/FJM.2002.6(2).15
- 邱浩彰（1998）。Neurology: Recent Advance in Migraine Studies。台灣醫學，2(5)，582-585。https://doi.org/10.6320/FJM.1998.2(5).14
- 台灣頭痛學會治療凖則小組（2007）。Treatment Guidelines for Acute Migraine Attacks。Acta Neurologica Taiwanica，16(4)，251-268。https://doi.org/10.29819/ANT.200712.0011
- 吳佩霖、黃秋谷、陳俊憲（2012）。Comparison of the Clinical Effects and Safety of Migraine Preventive Medications。臺灣臨床藥學雜誌，20(4)，285-300。https://www.airitilibrary.com/Article/Detail?DocID=10275096-201212-201301300039-201301300039-285-300